Clinical trial results:
A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multi-center Study of Eculizumab for the Prevention of Delayed Graft Function After Kidney Transplantation in Adult Subjects at Increased Risk of Delayed Graft Function.

Summary

EudraCT number	2013-004650-25
Trial protocol	DE IT ES CZ FR
Global end of trial date	22 November 2016

Results information

Result version number	v1 (current)
This version publication date	14 December 2017
First version publication date	14 December 2017

Trial information

Trial identification

Sponsor protocol code	ECU-DGF-201

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT02145182
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Alexion Pharmaceuticals Inc.
Sponsor organisation address	100 College St., New Haven CT, United States, 06510
Public contact	Study Director, Alexion Pharmaceuticals Inc., clinicaltrials@alexion.com
Scientific contact	Study Director, Alexion Pharmaceuticals Inc., clinicaltrials@alexion.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	14 July 2017
Is this the analysis of the primary completion data?	Yes
Primary completion date	22 November 2016
Global end of trial reached?	Yes
Global end of trial date	22 November 2016
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The purpose of this study was to determine if eculizumab is safe and could be used to prevent delayed graft function (DGF) following kidney transplantation.

Protection of trial subjects:

This study was conducted in accordance with International Conference on Harmonisation (ICH) Good Clinical Practice, and the principles of the Declaration of Helsinki, in addition to following the laws and regulations of the country or countries in which a study is conducted.

Background therapy:

As expected, concomitant medications were used by all 288 participants during the study, because immunosuppressants and prophylactic medications were required to maintain allograft function and prevent infection in participants undergoing kidney transplant.

Evidence for comparator: -

Actual start date of recruitment	21 August 2014
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Australia: 6
Country: Number of subjects enrolled	Brazil: 5
Country: Number of subjects enrolled	Canada: 9
Country: Number of subjects enrolled	Czech Republic: 25
Country: Number of subjects enrolled	France: 17
Country: Number of subjects enrolled	Germany: 19
Country: Number of subjects enrolled	Italy: 18
Country: Number of subjects enrolled	Spain: 55
Country: Number of subjects enrolled	United States: 134
Worldwide total number of subjects	288
EEA total number of subjects	134

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37	0

wk	
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	182
From 65 to 84 years	106
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

Fifty-nine centers in Australia, Brazil, Canada, Czech Republic, France, Germany, Italy, Spain, and the United States of America participated in this study. The study recruited participants who had been receiving dialysis for a median of approximately 50 months before undergoing transplantation and received a kidney from a deceased donor.

Pre-assignment

Screening details:

Written consent was provided prior to study-required assessments (N=333). Participants who passed screening (N=314) were vaccinated against Neisseria meningitidis. A total of 314 were randomized; of these, 286 underwent transplantation and received eculizumab or placebo. Two participants received placebo but withdrew prior to transplantation.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor, Data analyst, Carer, Assessor

Blinding implementation details:

Matching placebo intravenous (IV) solution will be administered to participants in the Placebo arm.

Arms

Are arms mutually exclusive?	Yes
Arm title	Eculizumab

Arm description:

Participants received 2 doses of eculizumab: the first dose was just prior to reperfusion of the allograft and the second dose was within 18 to 24 hours (h) of completion of administration of the first dose. Each dose of eculizumab was administered by IV infusion over 25 to 45 minutes (min). The first dose was 1200 milligrams (mg) in 240 milliliters (mL) (5 mg/mL); the second dose was 900 mg in 180 mL (5 mg/mL).

Arm type	Experimental
Investigational medicinal product name	eculizumab
Investigational medicinal product code	
Other name	Soliris
Pharmaceutical forms	Concentrate for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Two doses in total, each administered by IV infusion over 25 to 45 min. Dose 1: 1200 mg in 240 mL (5 mg/mL) just prior to reperfusion of the allograft. Dose 2: 900 mg in 180 mL (5 mg/mL) within 18 to 24 h of completion of administration of the first dose.

Arm title	Placebo

Arm description:

Participants received 2 doses of placebo (0.9% sodium chloride [NaCl]): the first dose was just prior to reperfusion of the allograft and the second dose was within 18 to 24 h of completion of administration of the first dose. Each dose of placebo was administered by IV infusion over 25 to 45 min. The first dose was 240 mL of 0.9% NaCl; the second dose was 180 mL of 0.9% NaCl.

Arm type	Placebo

Investigational medicinal product name	placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Two doses in total, each administered by IV infusion over 25 to 45 min. Dose 1: 240 mL of 0.9% NaCl just prior to reperfusion of the allograft. Dose 2: 180 mL of 0.9% NaCl within 18 to 24 h of completion of administration of the first dose.

Number of subjects in period 1	Eculizumab	Placebo
Started	142	146
Received at Least 1 Dose of Study Drug	142	146
Completed	124	130
Not completed	18	16
Adverse event, serious fatal	7	7
Consent withdrawn by subject	5	4
Adverse event, non-fatal	4	1
Pre-transplant withdrawal	-	2
Lost to follow-up	2	2

Baseline characteristics

Reporting groups	
Reporting group title	Eculizumab

Reporting group description:

Participants received 2 doses of eculizumab: the first dose was just prior to reperfusion of the allograft and the second dose was within 18 to 24 hours (h) of completion of administration of the first dose. Each dose of eculizumab was administered by IV infusion over 25 to 45 minutes (min). The first dose was 1200 milligrams (mg) in 240 milliliters (mL) (5 mg/mL); the second dose was 900 mg in 180 mL (5 mg/mL).

Reporting group title	Placebo

Reporting group description:

Participants received 2 doses of placebo (0.9% sodium chloride [NaCl]): the first dose was just prior to reperfusion of the allograft and the second dose was within 18 to 24 h of completion of administration of the first dose. Each dose of placebo was administered by IV infusion over 25 to 45 min. The first dose was 240 mL of 0.9% NaCl; the second dose was 180 mL of 0.9% NaCl.

Reporting group values	Eculizumab	Placebo	Total
Number of subjects	142	146	288
Age categorical Units: Subjects			
Age continuous Units: years			
arithmetic mean	57.5	57.1	
standard deviation	± 12.29	± 13.03	-
Gender categorical Units: Subjects			
Female	47	45	92
Male	95	101	196
Ethnicity Units: Subjects			
Hispanic or Latino	23	23	46
Not Hispanic or Latino	108	113	221
Unknown or Not Reported	11	10	21
Race/Ethnicity Units: Subjects			
American Indian or Alaskan Native	1	2	3
Asian	0	4	4
Black or African American	38	37	75
Native Hawaiian or Other Pacific Islander	1	0	1
White	88	92	180
Other	9	7	16
Multiple	1	1	2
Unknown	4	3	7

End points

End points reporting groups

Reporting group title	Eculizumab

Reporting group description:

Participants received 2 doses of eculizumab: the first dose was just prior to reperfusion of the allograft and the second dose was within 18 to 24 hours (h) of completion of administration of the first dose. Each dose of eculizumab was administered by IV infusion over 25 to 45 minutes (min). The first dose was 1200 milligrams (mg) in 240 milliliters (mL) (5 mg/mL); the second dose was 900 mg in 180 mL (5 mg/mL).

Reporting group title	Placebo

Reporting group description:

Participants received 2 doses of placebo (0.9% sodium chloride [NaCl]): the first dose was just prior to reperfusion of the allograft and the second dose was within 18 to 24 h of completion of administration of the first dose. Each dose of placebo was administered by IV infusion over 25 to 45 min. The first dose was 240 mL of 0.9% NaCl; the second dose was 180 mL of 0.9% NaCl.

Subject analysis set title	Full Analysis Set
Subject analysis set type	Full analysis

Subject analysis set description:

All participants who were randomized to treatment and received a deceased donor kidney transplant and at least 1 dose of study drug (placebo or eculizumab).

Primary: Percentage Of Participants With DGF In The First Seven Days Post-transplant

End point title	Percentage Of Participants With DGF In The First Seven Days Post-transplant

End point description:

Results are reported for the DGF composite endpoint, defined as the occurrence of DGF (dialysis for any reason in the first 7 days post transplantation), graft loss, death, or loss to follow-up (including discontinuation) in the first 7 days post transplantation and for each item of the composite endpoint.

End point type	Primary

End point timeframe:

First 7 days post transplantation

End point values	Eculizumab	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	142[1]	144[2]		
Units: Percentage of participants				
number (not applicable)				
DGF Composite	35.9	41.7		
DGF	33.8	39.6		
Death	0.0	1.4		
Graft Loss	0.7	3.5		
Lost to Follow-up (including discontinuation)	3.5	1.4		

Notes:

[1] - Full Analysis Set

[2] - Full Analysis Set

Statistical analyses

Statistical analysis title	Analysis of DGF composite
Comparison groups	Placebo v Eculizumab
Number of subjects included in analysis	286
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3983 [3]
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	0.81
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.49
upper limit	1.33

Notes:

[3] - Logistic regression results for the DGF composite, the effect of treatment adjusted for preservation type and donor type, and Irish score.

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Non-serious adverse events were required to be reported during the study up to 60 days after the last dose of study drug and serious adverse events were required to be reported during the study through 12 months of follow-up.

Assessment type	Systematic

Dictionary used

Dictionary name	MedDRA
Dictionary version	19.1

Reporting groups

Reporting group title	Eculizumab

Reporting group description:

Participants received 2 doses of eculizumab: the first dose was just prior to reperfusion of the allograft and the second dose was within 18 to 24 h of completion of administration of the first dose. Each dose of eculizumab was administered by IV infusion over 25 to 45 min. The first dose was 1200 mg in 240 mL (5 mg/mL); the second dose was 900 mg in 180 mL (5 mg/mL).

Reporting group title	Placebo

Reporting group description:

Participants received 2 doses of placebo (0.9% NaCl): the first dose was just prior to reperfusion of the allograft and the second dose was within 18 to 24 h of completion of administration of the first dose. Each dose of placebo was administered by IV infusion over 25 to 45 min. The first dose was 240 mL of 0.9% NaCl; the second dose was 180 mL of 0.9% NaCl.

Serious adverse events	Eculizumab	Placebo	
Total subjects affected by serious adverse events			
subjects affected / exposed	92 / 142 (64.79%)	102 / 146 (69.86%)	
number of deaths (all causes)	8	7	
number of deaths resulting from adverse events	8	7	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Parathyroid tumour benign			
subjects affected / exposed	0 / 142 (0.00%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal cell carcinoma			
subjects affected / exposed	1 / 142 (0.70%)	0 / 146 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Squamous cell carcinoma			

subjects affected / exposed	0 / 142 (0.00%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tonsil cancer			
subjects affected / exposed	0 / 142 (0.00%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular disorders			
Arteriovenous fistula			
subjects affected / exposed	1 / 142 (0.70%)	0 / 146 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Deep vein thrombosis			
subjects affected / exposed	1 / 142 (0.70%)	7 / 146 (4.79%)	
occurrences causally related to treatment / all	0 / 1	0 / 9	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhage			
subjects affected / exposed	0 / 142 (0.00%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertension			
subjects affected / exposed	0 / 142 (0.00%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertensive crisis			
subjects affected / exposed	0 / 142 (0.00%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypotension			
subjects affected / exposed	1 / 142 (0.70%)	3 / 146 (2.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lymphocele			

subjects affected / exposed	2 / 142 (1.41%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lymphorrhoea			
subjects affected / exposed	1 / 142 (0.70%)	0 / 146 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral arterial occlusive disease			
subjects affected / exposed	0 / 142 (0.00%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peripheral ischaemia			
subjects affected / exposed	2 / 142 (1.41%)	0 / 146 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Shock			
subjects affected / exposed	0 / 142 (0.00%)	2 / 146 (1.37%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vena cava thrombosis			
subjects affected / exposed	0 / 142 (0.00%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	2 / 142 (1.41%)	0 / 146 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chest pain			
subjects affected / exposed	1 / 142 (0.70%)	0 / 146 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Death			

subjects affected / exposed	1 / 142 (0.70%)	0 / 146 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
General physical health deterioration			
subjects affected / exposed	1 / 142 (0.70%)	0 / 146 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Generalised oedema			
subjects affected / exposed	1 / 142 (0.70%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyrexia			
subjects affected / exposed	4 / 142 (2.82%)	4 / 146 (2.74%)	
occurrences causally related to treatment / all	0 / 6	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Immune system disorders			
Anaphylactic shock			
subjects affected / exposed	0 / 142 (0.00%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Drug hypersensitivity			
subjects affected / exposed	2 / 142 (1.41%)	0 / 146 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Kidney transplant rejection			
subjects affected / exposed	4 / 142 (2.82%)	3 / 146 (2.05%)	
occurrences causally related to treatment / all	0 / 5	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal transplant failure			
subjects affected / exposed	0 / 142 (0.00%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			

Acute pulmonary oedema			
subjects affected / exposed	0 / 142 (0.00%)	2 / 146 (1.37%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute respiratory failure			
subjects affected / exposed	1 / 142 (0.70%)	0 / 146 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dyspnoea			
subjects affected / exposed	0 / 142 (0.00%)	3 / 146 (2.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung disorder			
subjects affected / exposed	1 / 142 (0.70%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung infiltration			
subjects affected / exposed	0 / 142 (0.00%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mediastinal haematoma			
subjects affected / exposed	0 / 142 (0.00%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pleural effusion			
subjects affected / exposed	2 / 142 (1.41%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary embolism			
subjects affected / exposed	1 / 142 (0.70%)	2 / 146 (1.37%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary haematoma			

subjects affected / exposed	1 / 142 (0.70%)	0 / 146 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary hypertension			
subjects affected / exposed	0 / 142 (0.00%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary oedema			
subjects affected / exposed	2 / 142 (1.41%)	2 / 146 (1.37%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory distress			
subjects affected / exposed	1 / 142 (0.70%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory failure			
subjects affected / exposed	3 / 142 (2.11%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychiatric disorders			
Bipolar disorder			
subjects affected / exposed	0 / 142 (0.00%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Confusional state			
subjects affected / exposed	1 / 142 (0.70%)	0 / 146 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mental status changes			
subjects affected / exposed	0 / 142 (0.00%)	2 / 146 (1.37%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Investigations			

Biopsy kidney abnormal			
subjects affected / exposed	1 / 142 (0.70%)	0 / 146 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood creatine increased			
subjects affected / exposed	3 / 142 (2.11%)	2 / 146 (1.37%)	
occurrences causally related to treatment / all	0 / 4	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Donor specific antibody present			
subjects affected / exposed	0 / 142 (0.00%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Liver function test abnormal			
subjects affected / exposed	0 / 142 (0.00%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urine output decreased			
subjects affected / exposed	0 / 142 (0.00%)	2 / 146 (1.37%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
Abdominal wound dehiscence			
subjects affected / exposed	0 / 142 (0.00%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Complications of transplanted kidney			
subjects affected / exposed	4 / 142 (2.82%)	4 / 146 (2.74%)	
occurrences causally related to treatment / all	0 / 4	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Delayed graft function			
subjects affected / exposed	0 / 142 (0.00%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Graft haemorrhage			
subjects affected / exposed	0 / 142 (0.00%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Graft loss			
subjects affected / exposed	0 / 142 (0.00%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Graft thrombosis			
subjects affected / exposed	1 / 142 (0.70%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Incision site haematoma			
subjects affected / exposed	1 / 142 (0.70%)	0 / 146 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Incisional hernia			
subjects affected / exposed	0 / 142 (0.00%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Perinephric collection			
subjects affected / exposed	0 / 142 (0.00%)	2 / 146 (1.37%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Perirenal haematoma			
subjects affected / exposed	1 / 142 (0.70%)	3 / 146 (2.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post procedural haematoma			
subjects affected / exposed	2 / 142 (1.41%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post procedural haematuria			

subjects affected / exposed	1 / 142 (0.70%)	0 / 146 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post procedural haemorrhage			
subjects affected / exposed	1 / 142 (0.70%)	2 / 146 (1.37%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Post procedural urine leak			
subjects affected / exposed	0 / 142 (0.00%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Procedural haemorrhage			
subjects affected / exposed	1 / 142 (0.70%)	0 / 146 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Seroma			
subjects affected / exposed	0 / 142 (0.00%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subcutaneous haematoma			
subjects affected / exposed	0 / 142 (0.00%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Toxicity to various agents			
subjects affected / exposed	1 / 142 (0.70%)	0 / 146 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Transplant dysfunction			
subjects affected / exposed	1 / 142 (0.70%)	2 / 146 (1.37%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ulna fracture			

subjects affected / exposed	1 / 142 (0.70%)	0 / 146 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary anastomotic leak			
subjects affected / exposed	1 / 142 (0.70%)	0 / 146 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wound decomposition			
subjects affected / exposed	1 / 142 (0.70%)	0 / 146 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wound evisceration			
subjects affected / exposed	0 / 142 (0.00%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Procedural hypotension			
subjects affected / exposed	1 / 142 (0.70%)	0 / 146 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			
Acute coronary syndrome			
subjects affected / exposed	0 / 142 (0.00%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute myocardial infarction			
subjects affected / exposed	0 / 142 (0.00%)	3 / 146 (2.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Angina unstable			
subjects affected / exposed	1 / 142 (0.70%)	0 / 146 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Arrhythmia			

subjects affected / exposed	1 / 142 (0.70%)	0 / 146 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrial fibrillation			
subjects affected / exposed	2 / 142 (1.41%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Atrial flutter			
subjects affected / exposed	1 / 142 (0.70%)	0 / 146 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac arrest			
subjects affected / exposed	0 / 142 (0.00%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac failure			
subjects affected / exposed	1 / 142 (0.70%)	3 / 146 (2.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac failure congestive			
subjects affected / exposed	0 / 142 (0.00%)	3 / 146 (2.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardio-respiratory arrest			
subjects affected / exposed	0 / 142 (0.00%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Ischaemic cardiomyopathy			
subjects affected / exposed	0 / 142 (0.00%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Myocardial ischaemia			

subjects affected / exposed	0 / 142 (0.00%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tachycardia			
subjects affected / exposed	1 / 142 (0.70%)	0 / 146 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ventricular fibrillation			
subjects affected / exposed	1 / 142 (0.70%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	1 / 1	0 / 1	
deaths causally related to treatment / all	1 / 1	0 / 1	
Ventricular tachycardia			
subjects affected / exposed	0 / 142 (0.00%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Nervous system disorders			
Cerebrovascular accident			
subjects affected / exposed	1 / 142 (0.70%)	3 / 146 (2.05%)	
occurrences causally related to treatment / all	0 / 1	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haemorrhage intracranial			
subjects affected / exposed	1 / 142 (0.70%)	0 / 146 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Headache			
subjects affected / exposed	0 / 142 (0.00%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hydrocephalus			
subjects affected / exposed	1 / 142 (0.70%)	0 / 146 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Loss of consciousness			

subjects affected / exposed	0 / 142 (0.00%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neuromyopathy			
subjects affected / exposed	1 / 142 (0.70%)	0 / 146 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neurotoxicity			
subjects affected / exposed	1 / 142 (0.70%)	0 / 146 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Posterior reversible encephalopathy syndrome			
subjects affected / exposed	1 / 142 (0.70%)	0 / 146 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Seizure			
subjects affected / exposed	0 / 142 (0.00%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Somnolence			
subjects affected / exposed	1 / 142 (0.70%)	0 / 146 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Status epilepticus			
subjects affected / exposed	0 / 142 (0.00%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Syncope			
subjects affected / exposed	1 / 142 (0.70%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tremor			

subjects affected / exposed	0 / 142 (0.00%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	5 / 142 (3.52%)	3 / 146 (2.05%)	
occurrences causally related to treatment / all	0 / 5	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Disseminated intravascular coagulation			
subjects affected / exposed	0 / 142 (0.00%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Febrile neutropenia			
subjects affected / exposed	0 / 142 (0.00%)	2 / 146 (1.37%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Leukopenia			
subjects affected / exposed	2 / 142 (1.41%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancytopenia			
subjects affected / exposed	1 / 142 (0.70%)	0 / 146 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombocytopenia			
subjects affected / exposed	1 / 142 (0.70%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombotic microangiopathy			
subjects affected / exposed	1 / 142 (0.70%)	2 / 146 (1.37%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Agranulocytosis			

subjects affected / exposed	0 / 142 (0.00%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Abdominal hernia			
subjects affected / exposed	1 / 142 (0.70%)	0 / 146 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal pain			
subjects affected / exposed	3 / 142 (2.11%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal pain lower			
subjects affected / exposed	1 / 142 (0.70%)	0 / 146 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anal fissure			
subjects affected / exposed	0 / 142 (0.00%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anal ulcer			
subjects affected / exposed	1 / 142 (0.70%)	0 / 146 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Chronic gastritis			
subjects affected / exposed	0 / 142 (0.00%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Constipation			
subjects affected / exposed	1 / 142 (0.70%)	0 / 146 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diarrhoea			

subjects affected / exposed	1 / 142 (0.70%)	0 / 146 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Duodenal ulcer haemorrhage			
subjects affected / exposed	0 / 142 (0.00%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dyspepsia			
subjects affected / exposed	1 / 142 (0.70%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Gastrointestinal disorder			
subjects affected / exposed	1 / 142 (0.70%)	0 / 146 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal obstruction			
subjects affected / exposed	1 / 142 (0.70%)	0 / 146 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haematochezia			
subjects affected / exposed	0 / 142 (0.00%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ileal perforation			
subjects affected / exposed	0 / 142 (0.00%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Inguinal hernia			
subjects affected / exposed	1 / 142 (0.70%)	0 / 146 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Internal hernia			

subjects affected / exposed	0 / 142 (0.00%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intra-abdominal fluid collection			
subjects affected / exposed	0 / 142 (0.00%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Megacolon			
subjects affected / exposed	1 / 142 (0.70%)	0 / 146 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mouth ulceration			
subjects affected / exposed	2 / 142 (1.41%)	0 / 146 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nausea			
subjects affected / exposed	1 / 142 (0.70%)	0 / 146 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophageal ulcer			
subjects affected / exposed	1 / 142 (0.70%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatitis			
subjects affected / exposed	0 / 142 (0.00%)	2 / 146 (1.37%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Retroperitoneal haematoma			
subjects affected / exposed	0 / 142 (0.00%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Upper gastrointestinal haemorrhage			

subjects affected / exposed	1 / 142 (0.70%)	0 / 146 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vomiting			
subjects affected / exposed	2 / 142 (1.41%)	2 / 146 (1.37%)	
occurrences causally related to treatment / all	0 / 4	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders			
Cholecystitis acute			
subjects affected / exposed	1 / 142 (0.70%)	0 / 146 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gallbladder perforation			
subjects affected / exposed	0 / 142 (0.00%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin and subcutaneous tissue disorders			
Angioedema			
subjects affected / exposed	1 / 142 (0.70%)	0 / 146 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic foot			
subjects affected / exposed	1 / 142 (0.70%)	0 / 146 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Panniculitis			
subjects affected / exposed	0 / 142 (0.00%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rash maculo-papular			
subjects affected / exposed	0 / 142 (0.00%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			

Acute kidney injury			
subjects affected / exposed	3 / 142 (2.11%)	6 / 146 (4.11%)	
occurrences causally related to treatment / all	0 / 3	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anuria			
subjects affected / exposed	0 / 142 (0.00%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Azotaemia			
subjects affected / exposed	1 / 142 (0.70%)	0 / 146 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bladder outlet obstruction			
subjects affected / exposed	0 / 142 (0.00%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Haematuria			
subjects affected / exposed	0 / 142 (0.00%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hydronephrosis			
subjects affected / exposed	2 / 142 (1.41%)	0 / 146 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mesangioproliferative glomerulonephritis			
subjects affected / exposed	0 / 142 (0.00%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nephrolithiasis			
subjects affected / exposed	1 / 142 (0.70%)	0 / 146 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nephropathy toxic			

subjects affected / exposed	2 / 142 (1.41%)	0 / 146 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Obstructive nephropathy			
subjects affected / exposed	1 / 142 (0.70%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal artery dissection			
subjects affected / exposed	0 / 142 (0.00%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal artery stenosis			
subjects affected / exposed	0 / 142 (0.00%)	3 / 146 (2.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal cyst haemorrhage			
subjects affected / exposed	1 / 142 (0.70%)	0 / 146 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal haematoma			
subjects affected / exposed	0 / 142 (0.00%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal impairment			
subjects affected / exposed	2 / 142 (1.41%)	3 / 146 (2.05%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal tubular necrosis			
subjects affected / exposed	1 / 142 (0.70%)	2 / 146 (1.37%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal vein thrombosis			

subjects affected / exposed	0 / 142 (0.00%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ureteric obstruction			
subjects affected / exposed	2 / 142 (1.41%)	0 / 146 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ureteric stenosis			
subjects affected / exposed	2 / 142 (1.41%)	2 / 146 (1.37%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urethral haemorrhage			
subjects affected / exposed	0 / 142 (0.00%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary fistula			
subjects affected / exposed	1 / 142 (0.70%)	0 / 146 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary retention			
subjects affected / exposed	1 / 142 (0.70%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract disorder			
subjects affected / exposed	1 / 142 (0.70%)	0 / 146 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract obstruction			
subjects affected / exposed	0 / 142 (0.00%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endocrine disorders			
Hyperparathyroidism			

subjects affected / exposed	1 / 142 (0.70%)	0 / 146 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperparathyroidism secondary			
subjects affected / exposed	1 / 142 (0.70%)	0 / 146 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			
Musculoskeletal pain			
subjects affected / exposed	1 / 142 (0.70%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Polyarthritis			
subjects affected / exposed	1 / 142 (0.70%)	0 / 146 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Abdominal abscess			
subjects affected / exposed	1 / 142 (0.70%)	0 / 146 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal sepsis			
subjects affected / exposed	1 / 142 (0.70%)	0 / 146 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Abscess limb			
subjects affected / exposed	0 / 142 (0.00%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bacteraemia			
subjects affected / exposed	1 / 142 (0.70%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Bacterial pyelonephritis			
subjects affected / exposed	1 / 142 (0.70%)	0 / 146 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bacterial sepsis			
subjects affected / exposed	2 / 142 (1.41%)	0 / 146 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchitis moraxella			
subjects affected / exposed	1 / 142 (0.70%)	0 / 146 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cellulitis			
subjects affected / exposed	0 / 142 (0.00%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Clostridium difficile colitis			
subjects affected / exposed	2 / 142 (1.41%)	0 / 146 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Clostridium difficile infection			
subjects affected / exposed	1 / 142 (0.70%)	0 / 146 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cytomegalovirus infection			
subjects affected / exposed	3 / 142 (2.11%)	2 / 146 (1.37%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cytomegalovirus viraemia			
subjects affected / exposed	3 / 142 (2.11%)	3 / 146 (2.05%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic foot infection			

subjects affected / exposed	0 / 142 (0.00%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Enterococcal bacteraemia			
subjects affected / exposed	0 / 142 (0.00%)	3 / 146 (2.05%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Enterococcal infection			
subjects affected / exposed	1 / 142 (0.70%)	0 / 146 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Enterococcal sepsis			
subjects affected / exposed	1 / 142 (0.70%)	0 / 146 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Epididymitis			
subjects affected / exposed	1 / 142 (0.70%)	0 / 146 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Escherichia bacteraemia			
subjects affected / exposed	1 / 142 (0.70%)	0 / 146 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Escherichia infection			
subjects affected / exposed	0 / 142 (0.00%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Escherichia pyelonephritis			
subjects affected / exposed	3 / 142 (2.11%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Escherichia sepsis			

subjects affected / exposed	0 / 142 (0.00%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Escherichia urinary tract infection			
subjects affected / exposed	3 / 142 (2.11%)	0 / 146 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gangrene			
subjects affected / exposed	2 / 142 (1.41%)	0 / 146 (0.00%)	
occurrences causally related to treatment / all	0 / 4	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis			
subjects affected / exposed	0 / 142 (0.00%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infected lymphocele			
subjects affected / exposed	1 / 142 (0.70%)	0 / 146 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infection			
subjects affected / exposed	1 / 142 (0.70%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Intervertebral discitis			
subjects affected / exposed	0 / 142 (0.00%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Klebsiella bacteraemia			
subjects affected / exposed	1 / 142 (0.70%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Klebsiella sepsis			

subjects affected / exposed	0 / 142 (0.00%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Liver abscess			
subjects affected / exposed	0 / 142 (0.00%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nocardiosis			
subjects affected / exposed	1 / 142 (0.70%)	0 / 146 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophageal candidiasis			
subjects affected / exposed	1 / 142 (0.70%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 2	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteomyelitis			
subjects affected / exposed	2 / 142 (1.41%)	0 / 146 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Peritonitis			
subjects affected / exposed	0 / 142 (0.00%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumocystis jirovecii pneumonia			
subjects affected / exposed	1 / 142 (0.70%)	0 / 146 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia			
subjects affected / exposed	7 / 142 (4.93%)	8 / 146 (5.48%)	
occurrences causally related to treatment / all	0 / 11	0 / 8	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia cytomegaloviral			

subjects affected / exposed	2 / 142 (1.41%)	0 / 146 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia mycoplasmal			
subjects affected / exposed	1 / 142 (0.70%)	0 / 146 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia pneumococcal			
subjects affected / exposed	1 / 142 (0.70%)	0 / 146 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia viral			
subjects affected / exposed	1 / 142 (0.70%)	0 / 146 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Polyomavirus-associated nephropathy			
subjects affected / exposed	0 / 142 (0.00%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Postoperative wound infection			
subjects affected / exposed	2 / 142 (1.41%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pseudomonal bacteraemia			
subjects affected / exposed	0 / 142 (0.00%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pseudomonal sepsis			
subjects affected / exposed	0 / 142 (0.00%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyelonephritis			

subjects affected / exposed	1 / 142 (0.70%)	2 / 146 (1.37%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyelonephritis acute			
subjects affected / exposed	1 / 142 (0.70%)	4 / 146 (2.74%)	
occurrences causally related to treatment / all	0 / 1	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory tract infection			
subjects affected / exposed	2 / 142 (1.41%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Salmonella sepsis			
subjects affected / exposed	0 / 142 (0.00%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sepsis			
subjects affected / exposed	2 / 142 (1.41%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 1	
Septic shock			
subjects affected / exposed	4 / 142 (2.82%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 1	
Staphylococcal sepsis			
subjects affected / exposed	1 / 142 (0.70%)	0 / 146 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Systemic candida			
subjects affected / exposed	0 / 142 (0.00%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Upper respiratory tract infection			

subjects affected / exposed	1 / 142 (0.70%)	0 / 146 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract infection			
subjects affected / exposed	7 / 142 (4.93%)	4 / 146 (2.74%)	
occurrences causally related to treatment / all	0 / 8	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract infection bacterial			
subjects affected / exposed	3 / 142 (2.11%)	2 / 146 (1.37%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract infection enterococcal			
subjects affected / exposed	1 / 142 (0.70%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urosepsis			
subjects affected / exposed	6 / 142 (4.23%)	3 / 146 (2.05%)	
occurrences causally related to treatment / all	0 / 7	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wound abscess			
subjects affected / exposed	1 / 142 (0.70%)	0 / 146 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
Acidosis			
subjects affected / exposed	0 / 142 (0.00%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Calciphylaxis			
subjects affected / exposed	0 / 142 (0.00%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Decreased appetite			

subjects affected / exposed	1 / 142 (0.70%)	0 / 146 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dehydration			
subjects affected / exposed	1 / 142 (0.70%)	0 / 146 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetes mellitus			
subjects affected / exposed	1 / 142 (0.70%)	0 / 146 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetes mellitus inadequate control			
subjects affected / exposed	1 / 142 (0.70%)	2 / 146 (1.37%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diabetic ketoacidosis			
subjects affected / exposed	1 / 142 (0.70%)	2 / 146 (1.37%)	
occurrences causally related to treatment / all	0 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Electrolyte imbalance			
subjects affected / exposed	0 / 142 (0.00%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Failure to thrive			
subjects affected / exposed	0 / 142 (0.00%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypercalcaemia			
subjects affected / exposed	1 / 142 (0.70%)	1 / 146 (0.68%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperglycaemia			

subjects affected / exposed	0 / 142 (0.00%)	2 / 146 (1.37%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperkalaemia			
subjects affected / exposed	9 / 142 (6.34%)	5 / 146 (3.42%)	
occurrences causally related to treatment / all	0 / 9	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyponatraemia			
subjects affected / exposed	0 / 142 (0.00%)	2 / 146 (1.37%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypovolaemia			
subjects affected / exposed	1 / 142 (0.70%)	0 / 146 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Eculizumab	Placebo	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	139 / 142 (97.89%)	142 / 146 (97.26%)	
Vascular disorders			
Hypertension			
subjects affected / exposed	34 / 142 (23.94%)	39 / 146 (26.71%)	
occurrences (all)	37	43	
Hypotension			
subjects affected / exposed	29 / 142 (20.42%)	33 / 146 (22.60%)	
occurrences (all)	31	37	
Lymphocele			
subjects affected / exposed	9 / 142 (6.34%)	4 / 146 (2.74%)	
occurrences (all)	10	4	
General disorders and administration site conditions			
Asthenia			

subjects affected / exposed	12 / 142 (8.45%)	20 / 146 (13.70%)	
occurrences (all)	12	23	
Chest pain			
subjects affected / exposed	6 / 142 (4.23%)	11 / 146 (7.53%)	
occurrences (all)	6	12	
Oedema			
subjects affected / exposed	7 / 142 (4.93%)	8 / 146 (5.48%)	
occurrences (all)	9	10	
Oedema peripheral			
subjects affected / exposed	41 / 142 (28.87%)	57 / 146 (39.04%)	
occurrences (all)	55	77	
Pyrexia			
subjects affected / exposed	26 / 142 (18.31%)	20 / 146 (13.70%)	
occurrences (all)	31	20	
Immune system disorders			
Kidney transplant rejection			
subjects affected / exposed	14 / 142 (9.86%)	7 / 146 (4.79%)	
occurrences (all)	16	7	
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	6 / 142 (4.23%)	9 / 146 (6.16%)	
occurrences (all)	6	10	
Dyspnoea			
subjects affected / exposed	10 / 142 (7.04%)	10 / 146 (6.85%)	
occurrences (all)	11	10	
Dyspnoea exertional			
subjects affected / exposed	1 / 142 (0.70%)	9 / 146 (6.16%)	
occurrences (all)	1	9	
Oropharyngeal pain			
subjects affected / exposed	5 / 142 (3.52%)	10 / 146 (6.85%)	
occurrences (all)	5	10	
Psychiatric disorders			
Anxiety			
subjects affected / exposed	10 / 142 (7.04%)	10 / 146 (6.85%)	
occurrences (all)	11	11	
Insomnia			

subjects affected / exposed	16 / 142 (11.27%)	16 / 146 (10.96%)	
occurrences (all)	18	16	
Investigations			
Blood creatine increased			
subjects affected / exposed	14 / 142 (9.86%)	21 / 146 (14.38%)	
occurrences (all)	14	21	
Urine output decreased			
subjects affected / exposed	5 / 142 (3.52%)	11 / 146 (7.53%)	
occurrences (all)	6	11	
Injury, poisoning and procedural complications			
Procedural pain			
subjects affected / exposed	30 / 142 (21.13%)	21 / 146 (14.38%)	
occurrences (all)	33	22	
Cardiac disorders			
Atrial fibrillation			
subjects affected / exposed	9 / 142 (6.34%)	10 / 146 (6.85%)	
occurrences (all)	14	11	
Tachycardia			
subjects affected / exposed	17 / 142 (11.97%)	12 / 146 (8.22%)	
occurrences (all)	20	13	
Nervous system disorders			
Dizziness			
subjects affected / exposed	5 / 142 (3.52%)	10 / 146 (6.85%)	
occurrences (all)	7	10	
Headache			
subjects affected / exposed	13 / 142 (9.15%)	10 / 146 (6.85%)	
occurrences (all)	13	11	
Tremor			
subjects affected / exposed	21 / 142 (14.79%)	28 / 146 (19.18%)	
occurrences (all)	21	29	
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	77 / 142 (54.23%)	75 / 146 (51.37%)	
occurrences (all)	90	82	
Leukocytosis			

subjects affected / exposed	8 / 142 (5.63%)	7 / 146 (4.79%)	
occurrences (all)	8	8	
Leukopenia			
subjects affected / exposed	37 / 142 (26.06%)	30 / 146 (20.55%)	
occurrences (all)	45	32	
Thrombocytopenia			
subjects affected / exposed	24 / 142 (16.90%)	15 / 146 (10.27%)	
occurrences (all)	24	15	
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	13 / 142 (9.15%)	14 / 146 (9.59%)	
occurrences (all)	13	15	
Constipation			
subjects affected / exposed	40 / 142 (28.17%)	40 / 146 (27.40%)	
occurrences (all)	44	48	
Diarrhoea			
subjects affected / exposed	37 / 142 (26.06%)	35 / 146 (23.97%)	
occurrences (all)	42	39	
Dyspepsia			
subjects affected / exposed	9 / 142 (6.34%)	8 / 146 (5.48%)	
occurrences (all)	11	8	
Nausea			
subjects affected / exposed	36 / 142 (25.35%)	32 / 146 (21.92%)	
occurrences (all)	48	36	
Vomiting			
subjects affected / exposed	30 / 142 (21.13%)	24 / 146 (16.44%)	
occurrences (all)	35	27	
Skin and subcutaneous tissue disorders			
Pruritus			
subjects affected / exposed	11 / 142 (7.75%)	9 / 146 (6.16%)	
occurrences (all)	11	9	
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	6 / 142 (4.23%)	10 / 146 (6.85%)	
occurrences (all)	6	11	
Bladder spasm			

subjects affected / exposed	6 / 142 (4.23%)	8 / 146 (5.48%)	
occurrences (all)	6	8	
Dysuria			
subjects affected / exposed	14 / 142 (9.86%)	20 / 146 (13.70%)	
occurrences (all)	14	20	
Haematuria			
subjects affected / exposed	14 / 142 (9.86%)	15 / 146 (10.27%)	
occurrences (all)	17	16	
Proteinuria			
subjects affected / exposed	8 / 142 (5.63%)	6 / 146 (4.11%)	
occurrences (all)	8	6	
Renal tubular necrosis			
subjects affected / exposed	15 / 142 (10.56%)	10 / 146 (6.85%)	
occurrences (all)	15	10	
Urinary retention			
subjects affected / exposed	8 / 142 (5.63%)	5 / 146 (3.42%)	
occurrences (all)	8	5	
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	12 / 142 (8.45%)	9 / 146 (6.16%)	
occurrences (all)	15	9	
Musculoskeletal pain			
subjects affected / exposed	10 / 142 (7.04%)	15 / 146 (10.27%)	
occurrences (all)	10	18	
Infections and infestations			
BK virus infection			
subjects affected / exposed	18 / 142 (12.68%)	18 / 146 (12.33%)	
occurrences (all)	21	19	
Cytomegalovirus infection			
subjects affected / exposed	17 / 142 (11.97%)	17 / 146 (11.64%)	
occurrences (all)	18	19	
Upper respiratory tract infection			
subjects affected / exposed	4 / 142 (2.82%)	10 / 146 (6.85%)	
occurrences (all)	4	11	
Urinary tract infection			

subjects affected / exposed	22 / 142 (15.49%)	33 / 146 (22.60%)	
occurrences (all)	27	44	
Metabolism and nutrition disorders			
Acidosis			
subjects affected / exposed	35 / 142 (24.65%)	24 / 146 (16.44%)	
occurrences (all)	42	24	
Decreased appetite			
subjects affected / exposed	3 / 142 (2.11%)	8 / 146 (5.48%)	
occurrences (all)	3	8	
Diabetes mellitus			
subjects affected / exposed	12 / 142 (8.45%)	6 / 146 (4.11%)	
occurrences (all)	12	6	
Diabetes mellitus inadequate control			
subjects affected / exposed	10 / 142 (7.04%)	15 / 146 (10.27%)	
occurrences (all)	10	16	
Fluid overload			
subjects affected / exposed	12 / 142 (8.45%)	26 / 146 (17.81%)	
occurrences (all)	14	28	
Hypercalcaemia			
subjects affected / exposed	11 / 142 (7.75%)	7 / 146 (4.79%)	
occurrences (all)	12	7	
Hyperglycaemia			
subjects affected / exposed	31 / 142 (21.83%)	23 / 146 (15.75%)	
occurrences (all)	34	23	
Hyperkalaemia			
subjects affected / exposed	59 / 142 (41.55%)	67 / 146 (45.89%)	
occurrences (all)	76	92	
Hyperphosphataemia			
subjects affected / exposed	13 / 142 (9.15%)	16 / 146 (10.96%)	
occurrences (all)	13	16	
Hypocalcaemia			
subjects affected / exposed	33 / 142 (23.24%)	23 / 146 (15.75%)	
occurrences (all)	37	24	
Hypoglycaemia			
subjects affected / exposed	7 / 142 (4.93%)	10 / 146 (6.85%)	
occurrences (all)	7	10	

Hypokalaemia			
subjects affected / exposed	12 / 142 (8.45%)	25 / 146 (17.12%)	
occurrences (all)	12	25	
Hypomagnesaemia			
subjects affected / exposed	40 / 142 (28.17%)	28 / 146 (19.18%)	
occurrences (all)	46	32	
Hyponatraemia			
subjects affected / exposed	8 / 142 (5.63%)	12 / 146 (8.22%)	
occurrences (all)	10	13	
Hypophosphataemia			
subjects affected / exposed	28 / 142 (19.72%)	19 / 146 (13.01%)	
occurrences (all)	29	20	
Vitamin D deficiency			
subjects affected / exposed	7 / 142 (4.93%)	8 / 146 (5.48%)	
occurrences (all)	7	8	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
29 September 2014	This amendment included the following changes: * The number of study centers was changed from 70 to 80 centers to more accurately reflect the number of centers for the ECU-DGF-201 study. * Listed all the diluents allowed per the protocol for the study drug preparation. * Specified that it was the investigative sites' responsibility to administer mycophenolate mofetil according to the instructions in the approved product label as per a United States Food and Drug Administration request. * Provided information on the type of vaccination for N meningitidis (a tetravalent [quadrivalent]) conjugated vaccine and specified that sites were permitted to use the serotype B vaccine for additional coverage when available. * Provided additional guidance for monitoring of anaphylactic reactions. * Specified that if an adverse event (AE) changed in severity over the duration of the event, this AE should not have been considered a new AE and the maximum (worst) severity should have been reported. * Updated the process of Investigator reporting of unexpected, serious, drug-related events.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

Because this was a negative study and did not demonstrate treatment effect, not all efficacy results are reported. Sample data were collected, but not analyzed to obtain outcome measure data. As such, a summary of these data sets is not possible.

Notes: